Related references
Note: Only part of the references are listed.Clinical presentation and management of acromegaly in elderly patients
Filippo Ceccato et al.
HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM (2021)
Association between biochemical control and comorbidities in patients with acromegaly: an Italian longitudinal retrospective chart review study
A. Colao et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2020)
Pasireotide for acromegaly: long- term outcomes from an extension to the Phase III PAOLA study
Annamaria Colao et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2020)
Therapeutic effect of presurgical treatment with longacting octreotide (Sandostatin® LAR®) in patients with acromegaly
Marek Bolanowski (Wrocław) et al.
Endokrynologia Polska (2020)
Multidisciplinary management of acromegaly: A consensus
Andrea Giustina et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2020)
Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study
Helene Lasolle et al.
ENDOCRINE CONNECTIONS (2019)
Diabetes in patients with acromegaly treated with pegvisomant: observations from acrostudy
Thierry Brue et al.
ENDOCRINE (2019)
Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study)
Ammar Muhammad et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Diabetes Secondary to Acromegaly: Physiopathology, Clinical Features and Effects of Treatment
Francesco Ferrau et al.
FRONTIERS IN ENDOCRINOLOGY (2018)
Efficacy and safety of switching to pasireotide in acromegaly patients controlled with pegvisomant and somatostatin analogues: PAPE extension study
Ammar Muhammad et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2018)
A Consensus Statement on acromegaly therapeutic outcomes
Shlomo Melmed et al.
NATURE REVIEWS ENDOCRINOLOGY (2018)
Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study
Ilan Shimon et al.
ENDOCRINE (2018)
Acromegaly at diagnosis in 3173 patients from the Liege Acromegaly Survey (LAS) Database
Patrick Petrossians et al.
ENDOCRINE-RELATED CANCER (2017)
Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry
Luigi Maione et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2017)
Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study
Maria Fleseriu et al.
ENDOCRINE (2017)
Management of Hyperglycemia in Patients With Acromegaly Treated With Pasireotide LAR
Susan L. Samson
DRUGS (2016)
Patient satisfaction and preferences of lanreotide Autogel treatment in acromegaly
Przemyslaw Witek et al.
ENDOKRYNOLOGIA POLSKA (2016)
Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly
Herbert A. Schmid et al.
ENDOCRINE (2016)
Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study
Michael Sheppard et al.
PITUITARY (2015)
Management of hyperglycemia associated with pasireotide (SOM230): Healthy volunteer study
Astrid Breitschaft et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2014)
Managing hyperglycemia in patients with Cushing's disease treated with pasireotide: medical expert recommendations
Annamaria Colao et al.
PITUITARY (2014)
Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial
Monica R. Gadelha et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Management of hyperglycaemia in Cushing's disease: Experts' proposals on the use of pasireotide
Y. Reznik et al.
DIABETES & METABOLISM (2013)
Effects of medical therapies for acromegaly on glucose metabolism
C. Urbani et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2013)
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Silvio E. Inzucchi et al.
DIABETES CARE (2012)
A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers
Georg Golor et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2012)
Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry
Sandrine Fieffe et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2011)
Effects of Somatostatin Analogs on Glucose Homeostasis: A Metaanalysis of Acromegaly Studies
Gherardo Mazziotti et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Medical progress: Acromegaly
Shlomo Melmed
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Share Paper
